3350 Stock Chart & Stats
€4.02
-€0.04(-1.25%)
At close: 4:00 PM EDT
€4.02
-€0.04(-1.25%)
Day’s Range― - ―
52-Week Range€1.66 - €4.26
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€160.24M
Enterprise Value€189.64M
Total Cash (Recent Filing)€189.98M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Nov 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.12
Shares Outstanding57,009,010
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.10
Price to Sales (P/S)20.96
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.86Price Target Upside70.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Capital BufferMinimal leverage reduces interest and refinancing pressure, while the larger equity base provides a stronger buffer for ongoing development spending. This improves near-term financial resilience, although it does not resolve the company’s persistent losses or cash consumption.
Experienced Oncology GovernanceAdding an experienced oncology and business-development leader can strengthen oversight and strategic decision-making as Whitehawk advances its pipeline. His background in launching oncology brands and scaling international operations is relevant to future commercialization execution.
Clinical-stage ADC PortfolioA focused clinical-stage antibody-drug conjugate portfolio gives the company a defined development strategy in oncology, where successful candidates could create meaningful future commercial opportunities. The portfolio also provides a platform for applying added strategic expertise.
Bears Say
Zero Trailing RevenueZero trailing revenue indicates that the company currently lacks a proven revenue engine and may remain dependent on development milestones rather than recurring commercial sales. This weakens operating visibility and leaves future value highly dependent on successful pipeline progress.
Persistent Large LossesLarge and sustained net losses show that current operations are not economically self-sustaining. Unless revenue scales materially or expenses decline, continued losses can erode the equity base, constrain strategic flexibility, and increase reliance on future financing.
Accelerating Cash BurnHeavy negative operating and free cash flow indicates that the business is consuming substantial cash while generating no current revenue. The deteriorating trend suggests limited self-funding capacity and potential dependence on external capital to sustain development over time.
Whitehawk Therapeutics News
3350 FAQ
What was Whitehawk Therapeutics’s price range in the past 12 months?
Whitehawk Therapeutics lowest stock price was €1.66 and its highest was €4.26 in the past 12 months.
What is Whitehawk Therapeutics’s market cap?
Whitehawk Therapeutics’s market cap is €160.24M.
When is Whitehawk Therapeutics’s upcoming earnings report date?
Whitehawk Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 14 days.
How were Whitehawk Therapeutics’s earnings last quarter?
Whitehawk Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.179 earnings per share for the quarter, beating the consensus estimate of -€0.265 by €0.086.
Is Whitehawk Therapeutics overvalued?
According to Wall Street analysts Whitehawk Therapeutics’s price is currently Undervalued.
Does Whitehawk Therapeutics pay dividends?
Whitehawk Therapeutics does not currently pay dividends.
What is Whitehawk Therapeutics’s EPS estimate?
Whitehawk Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Whitehawk Therapeutics have?
Whitehawk Therapeutics has 57,009,010 shares outstanding.
What happened to Whitehawk Therapeutics’s price movement after its last earnings report?
Whitehawk Therapeutics reported an EPS of -€0.179 in its last earnings report, beating expectations of -€0.265. Following the earnings report the stock price went down -0.578%.
Which hedge fund is a major shareholder of Whitehawk Therapeutics?
Currently, no hedge funds are holding shares in DE:3350
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Whitehawk Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.86 (70.72% Upside)
€6.86 (70.72% Upside)
Blogger Sentiment
Bullish
DE:3350 Sentiment 100%
Sector Average 66%
Sector Average 66%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.29%
12-Months-Change
Fundamentals
Return on Equity
-53.89%
Trailing 12-Months
Asset Growth
7.28%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Whitehawk Therapeutics
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
3350 Stock 12 Month Forecast
Average Price Target
€6.86
▲(70.72% Upside)